US2005014808A1PendingUtilityA1

Combined agents for treatment of glaucoma

56
Assignee: SANKYO COPriority: Dec 1, 1999Filed: Aug 10, 2004Published: Jan 20, 2005
Est. expiryDec 1, 2019(expired)· nominal 20-yr term from priority
Inventors:Tomihisa Yokoyama
A61P 9/12A61P 43/00A61K 45/06A61K 31/557A61K 31/44A61K 31/55A61P 27/06A61K 31/41A61K 31/535A61K 31/415A61K 31/4439
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and dorzolamide or a pharmacologically acceptable salt thereof, and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient. The angiotensin II antagonist is of the following formula (I) wherein R 1 represents a structural formula selected from the group consisting of:

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for the prophylaxis or treatment of glaucoma comprising a pharmaceutically effective amount of (i) an angiotensin II antagonist of the following formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof:  
       
         
           
           
               
               
           
         
       
       wherein R 1  represents a structural formula selected from the group consisting of  
       
         
           
           
               
               
           
         
       
       and (ii) dorzolamide or a pharmacologically acceptable salt thereof, either alone or in combination with a pharmaceutically acceptable carrier.  
     
     
         2 . The pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 , wherein a ratio of the angiotensin II antagonist (i) to the dorzolamide or pharmacologically acceptable salt thereof (ii) is 1:1 to 10:1.  
     
     
         3 . The pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 , wherein R 1  represents a structural formula having the formula (Ia).  
     
     
         4 . The pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 , wherein R 1  represents a structural formula having the formula (1b).  
     
     
         5 . The pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 , wherein R 1  represents a structural formula having the formula (1c).  
     
     
         6 . The pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 , wherein said (ii) is dorzolamide hydrochloride.  
     
     
         7 . The pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 , which is in a form suitable for topical administration to the eyes.  
     
     
         8 . A method for preventing or treating glaucoma comprising administering to a warm blooded animal in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 .  
     
     
         9 . A method for preventing glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 .  
     
     
         10 . A method for preventing glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 2 .  
     
     
         11 . A method for preventing glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 3 .  
     
     
         12 . A method for preventing glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 4 .  
     
     
         13 . A method for preventing glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 5 .  
     
     
         14 . A method for preventing glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 6 .  
     
     
         15 . A method for preventing glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 7 .  
     
     
         16 . A method for treating glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 1 .  
     
     
         17 . A method for treating glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 2 .  
     
     
         18 . A method for treating glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 3 .  
     
     
         19 . A method for treating glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 4 .  
     
     
         20 . A method for treating glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 5 .  
     
     
         21 . A method for treating glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 6 .  
     
     
         22 . A method for treating glaucoma comprising administering to a human in need thereof the pharmaceutical composition for the prophylaxis or treatment of glaucoma according to  claim 7 .  
     
     
         23 . A method for preventing or treating glaucoma comprising administering to a warm blooded animal a pharmaceutically effective amount of active ingredients, the active ingredients comprising (i) an angiotensin II antagonist of the following formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof:  
       
         
           
           
               
               
           
         
       
       , wherein R 1  represents a structural formula selected from the group consisting of  
       
         
           
           
               
               
           
         
       
       and (ii) dorzolamide or a pharmacologically acceptable salt thereof, the active ingredients (i) and (ii) being administered simultaneously, separately or successively.  
     
     
         24 . The method according to  claim 23 , wherein the warm blooded animal is a human.  
     
     
         25 . The method according to  claim 24 , wherein the method is for treating glaucoma.  
     
     
         26 . The method according to  claim 23 , wherein the method is for preventing glaucoma.  
     
     
         27 . The method according to  claim 23 , wherein R 1  is of the formula (Ia).  
     
     
         28 . The method according to  claim 23 , wherein R 1  is of the formula (Ib).  
     
     
         29 . The method according to  claim 23 , wherein R 1  is of the formula (Ic).

Join the waitlist — get patent alerts

Track US2005014808A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.